Current Report No. 24/2023 – Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the Company
28 December 2023 | Current reports
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date prepared: 12/22/2023, 10:59 a.m. In relation to the information provided in the periodical reports and, among others, in the recent periodical report for 3Q2023, regarding the planned marketing of new generic drugs in the area of cardiology in 2024, whichRead more »
Welcome to Celon Pharma S.A.
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
News
- Current Report No. 24/2023 – Decision of the President of the Office for Registration regarding the marketing authorization for a medicinal product of the CompanyLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date prepared: 12/22/2023, 10:59 a.m. In relation to the information provided in the periodical reports and,Read more »
- Current report No. 25/2023- Information concerning preliminary results of the phase 2a clinical trial on CPL’280 in treatment of type 2 diabetesSubject: Information concerning preliminary results of the phase 2a clinical trial on CPL’280 in treatment of type 2 diabetesLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR)Read more »
- Current report No. 23/2023 – Correction of the Periodical ReportLegal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information The Management Board of Celon Pharma S.A. (“Company”) hereby informs thatRead more »